270-OR: Loss of Myeloid IFNgamma Signaling Prevents Hepatic Inflammation and NASH in Obesity
Le résumé fourni par la source
Nonalcoholic steatohepatitis (NASH) is a major complication of obesity, and interferon-γ (IFNγ) is a key regulator of innate and adaptive immunity by priming macrophages and inducing an inflammatory response. We have recently generated mice with conditional deletion of IFNγ receptor in myeloid cells (Lyz-IFNγR2 KO) . After weeks of high-fat diet (HFD) , male KO and wild-type (WT) mice (n=6) developed fatty liver with a 70% increase in hepatic triglyceride levels compared to chow-fed mice (Figure 1; *P<0.vs. Chow) . Despite fatty liver, Luminex analysis found 20% to 80% decreases in intrahepatic levels of IL-1β, IL-7, IL-15, IFNγ, IL-9, KC, and MIG in KO mice (Figure 2; *P<0.vs. WT) . Next, male mice were fed with a methionine-choline deficient (MCD) diet (n=3) for NASH induction, and liver steatosis and fibrosis were noninvasively measured using Sonovol Ultrasound Imaging System. After 4 weeks of MCD diet, WT mice developed liver fibrosis, but KO mice showed significant attenuation of fibrosis, as indicated by a 20% decrease in liver stiffness (Figure 3) . Taken together, these results indicate that mice with conditional loss of IFNγ signaling in myeloid cells are protected from obesity-mediated hepatic inflammation and diet-induced NASH. In conclusion, our findings identify myeloid IFNγ signaling as a potential therapeutic target in treating metabolic liver disease. Disclosure R.H.Friedline: None. L.A.Tauer: None. W.Muller: None. J.K.Kim: n/a. M.Albusharif: None. H.Noh: n/a. A.M.Kim: None. L.H.Kim: None. D.X.T.Zheng: None. G.Swinand: None. A.Beaverson: None. X.Hu: None. Funding National Institutes of Health (5U2CDK093000)
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- 270-OR: Loss of Myeloid IFNgamma Signaling Prevents Hepatic Inflammation and NASH in Obesity
- Date Crossref
- 01/06/2022
- Éditeur
- American Diabetes Association
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.